<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008511</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1901</org_study_id>
    <secondary_id>IMPACT 20872</secondary_id>
    <nct_id>NCT04008511</nct_id>
  </id_info>
  <brief_title>Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase Ib/II Study of Regorafenib and XELOX Combination as 2nd Line Treatment in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, randomized open-label, parallel-group, multicenter, dose&#xD;
      escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd&#xD;
      line treatment in mCRC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ib/II trial, comprising Phase Ib and Phase II two parts. Phase Ib study is an&#xD;
      open-label, single-arm, multicenter, dose escalation study of Regorafenib plus XELOX. In&#xD;
      Phase Ib, max 15 patients(pts) could be enrolled based on the modified toxicity probability&#xD;
      interval (mTPI) design. Phase II study is a randomized, open-label, parallel-group,&#xD;
      multicenter study comparing Regorafenib + XELOX to XELOX alone. In phase II trial, a total of&#xD;
      39 patients will be recruited and randomized 2:1 into two groups, where 26 patients under&#xD;
      Regorafenib + XELOX, and 13 patients under XELOX alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The MTD is defined as the highest dose that can be given so that toxicity probability is below the target toxicity PT=30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time (days) from start of study treatment to date of first observed disease progression (investigator's radiological or clinical assessment) or death due to any cause, if death occurs before progression is documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>3 years</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>o DCR is defined as the percentage of patients, whose overall best response was not progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>o ORR is defined as the percentage of patients with complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:&#xD;
Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.</description>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 bid po for 14 days.</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130mg/m2, day 1, every 3 weeks</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign a consent form&#xD;
&#xD;
          2. Age&gt; 18 years &lt;75 years&#xD;
&#xD;
          3. Pathological diagnosis as colorectal adenocarcinoma&#xD;
&#xD;
          4. Recurrence or metastatic disease&#xD;
&#xD;
          5. Metastatic colorectal cancer with disease progression after 1st line treatment by 5-Fu&#xD;
             and Irinotecan&#xD;
&#xD;
          6. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          7. ECOG score 0-1 points&#xD;
&#xD;
          8. Life expectancy ≥3 months&#xD;
&#xD;
          9. Can provide more than 10 paraffin sections of tumor tissue&#xD;
&#xD;
         10. End of radiotherapy without or with non-targeted lesions&gt; 4 weeks (only for use&#xD;
             outside of the test site)&#xD;
&#xD;
         11. At least one measurable lesion (according to RECIST 1.1)&#xD;
&#xD;
         12. Previously treated radiotherapy lesions cannot be considered as target lesions, unless&#xD;
             the radiotherapy lesions clear progress.&#xD;
&#xD;
         13. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤ 2.5 times the&#xD;
             upper limit of normal (ULN), patients with liver metastases ≤ 5 times ULN&#xD;
&#xD;
         14. Serum albumin ≥ 3.0g / dL&#xD;
&#xD;
         15. Serum alkaline phosphatase (AKP) ≤2.5 times ULN&#xD;
&#xD;
         16. Total bilirubin &lt;1.5mg / dL&#xD;
&#xD;
         17. Estimated creatinine clearance (CLcr) ≥ 30 mL/min as calculated using the&#xD;
             Cockcroft-Gault equation&#xD;
&#xD;
         18. Lipase ≤ 1.5 x the ULN&#xD;
&#xD;
         19. Neutrophil absolute count (ANC) ≥ 1500 / mm3, hemoglobin (Hb)&gt; 9g/dl, platelets&gt;&#xD;
             100,000 / mm3&#xD;
&#xD;
         20. Pregnant or breast-feeding patients:&#xD;
&#xD;
        1) Women of childbearing potential and men must agree to use adequate contraception before&#xD;
        entering the program until at least 8 weeks after the last study drug administration. The&#xD;
        investigator or a designated associate is requested to advise the subject on how to achieve&#xD;
        an adequate birth control. Adequate contraception is defined in the study as any medically&#xD;
        recommended method (or combination of methods) as per standard of care.&#xD;
&#xD;
        2) Women of childbearing potential must have a blood or urine pregnancy test performed a&#xD;
        maximum of 7 days before start of study treatment, and a negative result must be documented&#xD;
        before start of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received oxaliplatin and capecitabine in the 1st line treatment&#xD;
&#xD;
          2. Cannot be orally administered&#xD;
&#xD;
          3. Subjects with brain metastases and / or cancerous meningitis.&#xD;
&#xD;
          4. Surgical treatment was performed within 4 weeks before enrollment (excluding&#xD;
             diagnostic biopsies)&#xD;
&#xD;
          5. Non-healing wound, non-healing ulcer, or non-healing bone fracture&#xD;
&#xD;
          6. Patients with evidence or history of any bleeding diathesis, irrespective of severity&#xD;
&#xD;
          7. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of&#xD;
             study medication.&#xD;
&#xD;
          8. Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within 6 months before the start of study medication (except for adequately treated&#xD;
             catheter-related venous thrombosis occurring more than one month before the start of&#xD;
             study medication)&#xD;
&#xD;
          9. Congestive heart failure ≥ New York Heart Association (NYHA) class 2&#xD;
&#xD;
         10. Uncontrolled cardiac arrhythmias&#xD;
&#xD;
         11. Ongoing infection &gt; Grade 2 NCI CTCAE&#xD;
&#xD;
         12. Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent.&#xD;
&#xD;
         13. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation.&#xD;
&#xD;
         14. Anti-tumor cytotoxic drug therapy, biologic medication (eg, monoclonal antibody),&#xD;
             immunotherapy (eg, interleukin 2 or interferon), or other investigational drug therapy&#xD;
             within 4 weeks prior to enrollment&#xD;
&#xD;
         15. Subjects with active tuberculosis (TB) who are on anti-TB treatment or who have&#xD;
             received anti-TB treatment within 1 year prior to screening&#xD;
&#xD;
         16. Patients with complications requiring long-term use of immunosuppressive drug therapy&#xD;
             or systemic or topical corticosteroids requiring immunosuppressive doses (prednisone&#xD;
             or other equivalent hormones at doses&gt; 10 mg / day)&#xD;
&#xD;
         17. Use of strong CYP3A4 inducers or inhibitors&#xD;
&#xD;
         18. In the first 4 weeks before the group vaccinated any anti-infective vaccine (such as&#xD;
             influenza vaccine, varicella vaccine, etc.)&#xD;
&#xD;
         19. Pregnancy or lactation&#xD;
&#xD;
         20. 5 years with other malignancies, except for non-melanoma skin cancer&#xD;
&#xD;
         21. Persistent proteinuria &gt; 3.5 g/24 hours measured by urine protein-creatinine ratio&#xD;
             from a random urine sample (Grade 3, NCI-CTCAE v 5.0).&#xD;
&#xD;
         22. Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
         23. Hepatitis B surface antigen (HBsAg) positive simultaneous detection of Hepatitis B&#xD;
             virus (HBV) Deoxyribonucleic acid (DNA) copy number positive (quantitative detection ≥&#xD;
             1000cps / ml)&#xD;
&#xD;
         24. Chronic hepatitis C blood screening positive [Hepatitis C virus (HCV) antibody&#xD;
             positive]&#xD;
&#xD;
         25. No legal capacity&#xD;
&#xD;
         26. Any other disease or condition that the investigator considers may affect program&#xD;
             adherence or affect the subject's signature of informed consent (ICF), or are not&#xD;
             suitable for participating in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunpeng Liu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunpeng Liu, M.D.,Ph.D.</last_name>
    <phone>86-24-83282312</phone>
    <email>cmu_trial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiujuan Qu, M.D.,Ph.D.</last_name>
    <phone>86-24-83282312</phone>
    <email>cmuquxiujuan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Regorafenib</keyword>
  <keyword>Second line</keyword>
  <keyword>XELOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

